USANA Health Sciences, Inc. (NYSE:USNA) Insider Brent Neidig Sells 2,694 Shares of Stock

Posted by on May 10th, 2023

USANA Health Sciences, Inc. (NYSE:USNA – Get Rating) insider Brent Neidig sold 2,694 shares of the firm’s stock in a transaction on Friday, May 5th. The stock was sold at an average price of $66.96, for a total transaction of $180,390.24. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Brent Neidig also recently made the following trade(s):

  • On Thursday, February 9th, Brent Neidig sold 1,872 shares of USANA Health Sciences stock. The stock was sold at an average price of $61.89, for a total transaction of $115,858.08.

USANA Health Sciences Stock Down 1.5 %

Shares of NYSE USNA opened at $65.38 on Wednesday. USANA Health Sciences, Inc. has a 52 week low of $48.61 and a 52 week high of $76.58. The firm has a 50-day moving average price of $63.45 and a 200 day moving average price of $58.37. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of 19.29 and a beta of 0.78.

USANA Health Sciences (NYSE:USNA – Get Rating) last announced its quarterly earnings data on Tuesday, February 7th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.35 by $0.31. USANA Health Sciences had a net margin of 6.70% and a return on equity of 15.31%. The firm had revenue of $227.96 million during the quarter. During the same quarter last year, the business earned $1.03 EPS. Equities research analysts expect that USANA Health Sciences, Inc. will post 3.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

USNA has been the subject of several recent analyst reports. DA Davidson raised their target price on shares of USANA Health Sciences from $52.50 to $56.00 in a research note on Wednesday, April 26th. StockNews.com upgraded shares of USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 10th.

Institutional Trading of USANA Health Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Parallel Advisors LLC raised its position in USANA Health Sciences by 225.0% during the fourth quarter. Parallel Advisors LLC now owns 533 shares of the company’s stock worth $28,000 after acquiring an additional 369 shares during the last quarter. US Bancorp DE raised its position in USANA Health Sciences by 64.3% during the first quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $39,000 after acquiring an additional 243 shares during the last quarter. Signaturefd LLC raised its position in USANA Health Sciences by 61.3% during the fourth quarter. Signaturefd LLC now owns 637 shares of the company’s stock worth $34,000 after acquiring an additional 242 shares during the last quarter. Covestor Ltd raised its position in USANA Health Sciences by 92.7% during the first quarter. Covestor Ltd now owns 927 shares of the company’s stock worth $74,000 after acquiring an additional 446 shares during the last quarter. Finally, Quadrant Capital Group LLC raised its position in USANA Health Sciences by 318.1% during the third quarter. Quadrant Capital Group LLC now owns 949 shares of the company’s stock worth $53,000 after acquiring an additional 722 shares during the last quarter. Institutional investors and hedge funds own 52.62% of the company’s stock.

USANA Health Sciences Company Profile

(Get Rating)

USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. It operates under the following segments: USANA Nutritionals, USANA Foods, Personal Care and Skincare, and All Other. The firm’s brands include Procosa and MagneCal D. The company was founded by Myron W.

Read More

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.